Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Chinook Therapeutics (Nasdaq: KDNY) announced an employment inducement grant of stock options for 150,000 shares to a new hire.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Chinook Therapeutics (Nasdaq: KDNY) announced an employment inducement grant of stock options for 150,000 shares to a new hire. The options have an exercise price of $12.90, equivalent to the stock's closing price on January 31, 2022. Vesting occurs over four years, with 25% on the start date and the remainder monthly. This grant adheres to Nasdaq's listing Rule 5635(c)(4). Chinook specializes in precision medicines for kidney diseases, with its lead program, atrasentan, currently in Phase 3 trials for IgA nephropathy.
Positive
- Inducement grant of stock options for 150,000 shares could attract skilled talent.
- Exercise price linked to the recent stock closing price indicates a fair valuation.
Negative
- None.
Details
News Market Reaction – KDNY
The recorded move for KDNY in the trading session of this news was +3.33%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved a new employment inducement grant of stock options to purchase 150,000 shares of common stock with a grant date of January 31, 2022 (the “Inducement Grant”) to one new employee.
The stock options approved under the Inducement Grant were issued on terms substantially similar to Chinook’s 2015 Equity Incentive Plan and have an exercise price per share equal to
The Company granted the stock options as a material inducement to this employee for entering into employment with Chinook Therapeutics, Inc. in accordance with Nasdaq listing Rule 5635(c)(4).
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.